Cholinergic activity and amyloid precursor protein metabolism

Brain Research Reviews

Volumn 25, Issue 1, 1997, Pages 50-69

  Roberson, Melinda R ^a   Harrell, Lindy E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

amyloid; Alzheimer's disease; Amyloid precursor protein; Basal forebrain; Cholinergic; Hippocampus; Muscarinic receptor; Nucleus basalis of Meynert

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; FOREBRAIN; HIPPOCAMPUS; HUMAN; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROCESSING; REVIEW; SENILE PLAQUE;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; HIPPOCAMPUS; HUMANS; LEARNING; MEMORY; MODELS, NEUROLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, MUSCARINIC;

EID: 0030772890     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(97)00016-7     Document Type: Review

References (184)

1. R.T. Bartus, Aging in the rhesus monkey: specific behavioral impairments and effects of pharmacological intervention, in: H. Orimo, K. Shimado, M. Iriki and D. Maeda (Eds.), Recent Advances in Gerontology, Proceedings of the XI International Congres on Gerontology, Excerpta Medica, Amsterdam, 1979, pp. 225-227.
2. Bartus R.T., Dean R.L., Beer B. Memory deficits in aged Cebus monkeys and facilitation with central cholinomimetics. Neurobiol. Aging. 1:1980;145-152.
3. R.T. Bartus, R.L. Dean, M.J. Pontecorvo and C. Flicker, The cholinergic hypothesis: a historical overview, current perspective, and future directions, in: D.S. Olton, E. Gamzu and S. Corkin (Eds.), Memory Dysfunctions: an Integration of Animal and Human Research from Preclinical and Clinical Perspectives, vol. 444, New York Academy of Sciences, 1985, pp. 332-358.
4. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
5. Bartus R.T., Fleming D., Johnson H.R. Aging in the rhesus monkey: debilitating effects on short-term memory. J. Gerontol. 33:1978;858-871.
6. Bartus R.T., Johnson H.R. Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol. Biochem. Behav. 5:1976;39-46.
7. Bergamaschi S., Binetti G., Govoni S., Wetsel W.C., Battaini F., Trabucchi M., Bianchetti A., Racchi M. Defective phorbol ester-stimulated secretion of β-amyloid precursor protein from Alzheimer's disease fibroblasts. Neurosci. Lett. 201:1995;1-4.
8. K.L. Bick, The early story of Alzheimer's Disease, in: R.D. Terry, R. Katzman and K.L. Bick (Eds.), Alzheimer's Disease, Raven Press, New York, 1994, pp. 1-8.
9. Blessed G., Tomlinson B.E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Brit. J. Psychiat. 114:1968;797-811.
10. Bliss T.V.P., Collingridge G.A. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
11. Bowes M.P., Masliah E., Otero D.A., Zivin J.A., Saitoh T. Reduction of neurological damage by a peptide sequence of the amyloid β/A4 protein precursor in a rabbit spinal cord ischemia model. Exp. Neurol. 129:1994;112-119.
12. Breitner J.C.S. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol. Aging. 17(5):1996;789-794.
13. Buxbaum J.D., Gandy S.E., Cicchetti P., Ehrlich M.E., Czernik A.J., Fracasso R.P., Ramabhadran T.V., Unterbeck A.J., Greengard P. Processing of Alzheimer β/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc. Natl. Acad. Sci. USA. 87:1990;6003-6006.
14. Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffee E.A., Gandy S.E., Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA. 89:1992;10075-10078.
15. Caporaso G.L., Gandy S.E., Buxbaum J.D., Greengard P. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer β/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 89:1992;3055-3059.
16. Caporaso G.L., Gandy S.E., Buxbaum J.D., Ramabhadran T.V., Greengard P. Protein phosphorylation regulates secretion of Alzheimer β/A4 amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 89:1992;2252-2256.
17. Carlisimo G.A. Memory deficits in Alzheimer's patients: a comprehensive review. Neuropsy. Rev. 3(2):1993;119-169.
18. N.J. Cohen, Different systems underlie acquisition of procedural and declarative knowledge, in: D.S. Olton, E. Gamzu and S. Corkin (Eds.), Memory Dysfunctions: an Integration of Animal and Human Research from Preclinical and Clinical Perspectives, vol. 444, New York Academy of Sciences, 1985, pp. 54-71.
19. Cole G., Dobkins K.R., Hansen L.A., Terry R.D., Saitoh T. Decreased levels of protein kinase C in Alzheimer brain. Brain Res. 452:1988;165-170.
20. J.R. Cooper, F.E. Bloom and R.H. Roth, The Biochemical Basis of Neuropharmacology, Sixth Edition, Oxford University Press, New York, 1991, pp. 190-219.
21. C.W. Cotman and C.J. Pike, β-Amyloid and its contributions to neurodegeneration in Alzheimer's disease, in: R.D. Terry, R. Katzman and K.L. Bick (Eds.), Alzheimer's Disease, Raven Press, New York, 1994, pp. 305-315.
22. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's Disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
23. Crutcher K.A., Scott S.A., Liang S., Everson W.V., Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J. Neurosci. 13(6):1993;2540-2550.
24. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Meher M., Masdeu J., Kawas C., Aronson M., Wolfson L. Clinico-pathologic studies in dementia: non-demented subjects with pathologically confirmed Alzheimer's disease. Neurology. 38:1988;1682-1687.
25. Czech C., Masters C., Beyreuther K. Alzheimer's disease and transgenic mice. J. Neural. Trans. 44(Suppl):1994;219-230.
26. P. Davies, A critical review of the role of the cholinergic system in human memory and cognition, in: D.S. Olton, E. Gamzu and S. Corkin (Eds.), Memory Dysfunctions: an Integration of Animal and Human Research from Preclinical and Clinical Perspectives, vol. 444, New York Academy of Sciences, 1985, pp. 332-358.
27. P. Davies, Neuronal abnormalities, not amyloid, are the cause of dementia in Alzheimer's disease, in: R.D. Terry, R. Katzman and K.L. Bick (Eds.), Alzheimer's Disease, Raven Press, New York, 1994.
28. Davies P., Verth A.H. Regional distribution of muscarinic acetylcholine receptors in normal and Alzheimer's-type dementia brains. Brain Res. 138:1978;385-392.
29. Davis R.E., Doyle P.D., Carroll R.T., Emmerling M.R., Jaen J. Cholinergic therapies for Alzheimer's disease: palliative or disease altering? Arzneim.-Forsch./Drug Res. 45(3A):1995;425-431.
30. Dean R.L., Beer B., Bartus R.T. Drug induced memory impairments in non-human primates. Neurosci. Abstr. 8:1982;322.
31. DeKosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A., Chui H.C., Knopman D.S., Reeder T.M., Shetter A.G., Senter H.J., Markesbery W.R. Cortical biopsy in Alzheimer's Disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlates. Ann. Neurol. 32(5):1992;625-632.
32. DeKosky S., Schepp S. Synaptic loss in frontal cortex biopsies in Alzheimer's Disease: correlate with cognitive severity. Ann. Neurol. 27:1990;457-464.
33. de Serres M., Sherman D., Chestnut W., Mreeill G.B.M., Viveros O.H., Diliberto E.J. Jr. Proteolysis at the secretase and amyloidogenic cleavage sites of the β-amyloid precursor protein by acetylcholinesterase and butyrylcholinesterase using model peptide substrates. Cell. Molec. Neurobiol. 13(3):1993;279-287.
34. Drachman D.A. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology. 27:1977;783-790.
35. Drachman D., Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch. Neurol. 30:1974;113-121.
36. Drachman D.A., Noffsinger D., Shahkian B.J., Kurdziel S., Fleming P. Aging, memory, and the cholinergic system: a study of dichotic listening. Neurobiol. Aging. 1:1980;39-43.
37. Drachman D.A., Friedland R.P., Larson E.B., Williams M.E. Making sure it's really Alzheimer's. Patient Care. 25(18):1991;13-40.
38. Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.G., Kang J., Muller-Hill B., Masters C.L., Beyreuther K. Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO J. 7(4):1988;949-957.
39. Dyrks T., Monning U., Beyreuther K., Turner J. Amyloid precursor protein secretion and βA4 amyloid generation are not mutually exclusive. FEBS Lett. 349:1994;210-214.
40. Esch F.S., Keim P.S., Beattie E.C., Blacher R.W., Culwell A.R., Oltersdorf T., McClure D., Ward P.J. Cleavage of amyloid β peptide during constitutive processing of its precursor. Science. 248:1990;1122-1124.
41. Estus S., Golde T.E., Kunishita T., Blades D., Lowery D., Eisen M., Usiak M., Qu X., Tabira T., Greenberg B.D., Younkin S.G. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science. 255:1992;726-728.
42. Farlow M., Ghetti B., Benson M.D., Farrow J.S., van Nostrand W.E., Wagner S.L. Low cerebrospinal-fluid concentrations of soluble amyloid β-protein precursor in hereditary Alzheimer's disease. Lancet. 340:1992;453-454.
43. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA. 268(18):1992;2523-2529.
44. Felder C.C., Ma A.L., Briley E.M., Axelrod J. Muscarinic acetylcholine receptor subtypes associated with release of Alzheimer amyloid precursor derivatives activate multiple signal transduction pathways. Ann. N.Y. Acad. Sci. 695:1993;15-18.
45. Felsenstein K.M., Ingalls K.M., Hunihan L.W., Roberts S.B. Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate. Neurosci. Lett. 174(2):1994;173-176.
46. Fordyce D.E., Wehner J.M. Effects of aging on spatial learning and hippocampal protein kinase C in mice. Neurobiol. Aging. 14:1993;309-317.
47. Fordyce D.E., Wehner J.M. Physical activity enhances spatial learning performance with an associated alteration in hippocampal protein kinase C activity in C57BL/6 and DBA/2 mice. Brain Res. 619:1993;111-119.
48. Frautschy S.A., Yang F., Calderon L., Cole G.M. Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol. Aging. 17(2):1996;311-322.
49. Fukuchi K.-I., Kamino K., Deeb S.S., Smith A.C., Dang T., Martin G.M. Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity. Biochem. Biophys. Res. Commun. 182(1):1992;165-173.
50. Gabuzda D., Busciglio J., Yankner B.A. Inhibition of β-amyloid production by activation of protein kinase C. J. Neurochem. 61(6):1993;2326-2329.
51. Gage F.H., Armstrong D.M., Williams L.W., Varon S. Morphological response of axotomized septal neurons to nerve growth factor. J. Comp. Biol. 269:1988;147-155.
52. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagoplan S., Johnson-Wood K., Khan K., Lee M., Leibowitz E., McConloque L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Woiozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
53. Gillespie S.L., Golde T.E., Younkin S.G. Secretory processing of the Alzheimer's amyloid beta/A4 protein precursor is increased by protein phosphorylation. Biochem. Biophys. Res. Commun. 187(3):1992;1285-1290.
54. Ginsberg L., Atack J.R., Rapoport S.I., Gershfeld N.L. Regional specificity of membrane instability in Alzheimer's disease brain. Brain Res. 615:1993;355-357.
55. Goedert M., Fine A., Hunt S.P., Ullrich A. Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Mol. Brain Res. 1:1986;85-92.
56. Golde T.E., Estus S., Younkin L.H., Selkoe D.J., Younkin S.G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 255:1992;728-730.
57. Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science. 235:1987;877-880.
58. Grabowska A., Luczywek E., Fersten E., Herman A., Szatkowska I. Memory impairment in patients with stereotaxic lesions to the hippocampus and amygdala. Acta Neurobiol. Exp. 54(4):1994;393-403.
59. Greenwood A.F., Powers R.E., Jope R.S. Phosphoinositide hydrolysis, Gαq, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Neuroscience. 69(1):1995;125-138.
60. W.S.T. Griffin, J.G. Sheng, R.E. Mrak, Inflammatory Pathways, in: W. Wasco and R.E. Tanzi (Eds.), Molecular Mechanisms of Dementia, Humana Press, Totowa, NJ, 1996, pp. 169-176.
61. Haass C., Koo E.H., Mellon A., Hung A.Y., Selkoe D.J. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 357:1992;500-502.
62. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. TIPS. 12:1991;383-388.
63. Hardy J.A., Higgins G.A. Alzheimer's Disease: the amyloid cascade hypothesis. Science. 256:1992;184-185.
64. Haring R., Gurwitz D., Barg J., Pinkas-Kramarski R., Heldman E., Pittell Z., Danenberg H.D., Wengier A., Meshulam H., Marciano D. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. Biochem. Biophys. Res. Commun. 213(1):1995;15-23.
65. Harkany T., Lengyel Z., Soos K., Penke B., Luiten P.G.M., Gulya K. Cholinotoxic effects of β-amyloid (1-42) peptide on cortical projections of the rat nucleus basalis magnocellularis. Brain Res. 695:1995;71-75.
66. Harrell L.E., Ayyagari V., Peagler A., Parsons D.S. Hippocampal sympathetic ingrowth and cholinergic denervation alter hippocampal muscarinic cholinergic receptors. Hippocampus. 4(2):1994;199-203.
67. Harrell L.E., Kolasa K., Parsons D.S., Ayyagari V. Hippocampal sympathetic ingrowth and cholinergic denervation uniquely alter muscarinic receptor subtypes in the hippocampus. Brain Res. 676:1995;386-393.
68. Harrigan M.R., Kunkel D.D., Nguyen L.B., Malouf A.T. β-amyloid is neurotoxic in hippocampal slice cultures. Neurobiol. Aging. 16(5):1995;779-789.
69. Hefti F. Is Alzheimer's disease caused by a lack of nerve growth factor? Ann. Neurol. 13:1983;109-110.
70. Higgins L.S., Holtzman D.M., Rabin J., Mobley W.C., Cordell B. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Annals Neurol. 35(5):1994;598-607.
71. Howlett L.R., Jennings K.H., Lee D.C., Brown F., Wetzel R., Wood S.J., Camilleri P., Roberts G.W. Aggregation state and neurotoxic properties of Alzheimer β-amyloid protein. Neurodegeneration. 4(1):1995;23-32.
72. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
73. Huerta P.T., Lisman J.E. Bidirectional synaptic plasticity induced by a single burst during cholinergic theta oscillation in CA1 in vitro. Neuron. 15(5):1995;1053-1063.
74. Huerta P.T., Lisman J.E. Heightened synaptic plasticity of hippocampal CA1 neurons during a cholinergically induced rhythmic state. Nature. 364(6439):1993;723-725.
75. Hung A.Y., Haass C., Nitch R.M., Qiu W.Q., Citron M., Wurtman R.J., Growdon J.H., Selkoe D.J. Activation of protein kinase C inhibits cellular production of amyloid beta-protein. J. Biol. Chem. 268(31):1993;22959-22962.
76. Hung A.Y., Selkoe D.J. Selective ectodomain phosphorylation and regulated cleavage of β-amyloid precursor protein. EMBO J. 13(3):1994;534-542.
77. Itoh A., Nitta A., Nadai M., Nishimura K., Hirose M., Hasegawa T., Nabeshima T. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J. Neurochem. 66(3):1996;1113-1117.
78. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., Shearman M.S. The toxicity in vitro of β-amyloid protein. Biochem. J. 311:1995;1-16.
79. Jette N., Cole M.S., Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol. Brain Res. 25:1994;242-250.
80. Jin L.W., Saitoh T. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. Drugs and Aging. 6(2):1995;136-149.
81. Jope R.S., Song L., Li X., Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol. Aging. 15(2):1994;221-226.
82. Kartsounis L.D., Rudge P., Stevens J.M. Bilateral lesions of CA1 and CA2 fields of the hippocampus are sufficient to cause a severe amnesic syndrome in humans. J. Neurol. Neurosurg. Psychiatry. 59(1):1995;95-98.
83. Katzman R., Terry R., DeTeresa R., Brown T., Davies P., Fuld P., Renbing X., Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23(2):1988;138-144.
84. Kinouchi T., Sorimachi H., Maruyama K., Mizuno K., Ohno S., Ishiura S., Suzuki K. Conventional protein kinase C (PKC)-alpha and novel PKC-epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. FEBS Lett. 364(2):1995;203-206.
85. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 271(13):1994;985-991.
86. Koo E.H., Sisodia S.S., Archer D.R., Martin L.J., Weidemann A., Beyreuther K., Fischer P., Masters C.L., Price D.L. Precursor of amyloid protein in Alzheimer's disease undergoes fast axonal transport. Proc. Natl. Acad. Sci. USA. 87(4):1990;1561-1565.
87. Kowall N.W., McKee A.C., Yankner B.A., Beal M.F. In vivo neurotoxicity of β-amyloid [(β (1-40)] and the β (25-35) fragment. Neurobiol. Aging. 13(5):1992;537-542.
88. Lahiri D.K. Reversibility of the effect of tacrine on the secretion of the β-amyloid precursor protein in cultured cells. Neurosci. Lett. 181(1-2):1994;149-152.
89. Lahiri D.K., Lewis S., Farlow M.R. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J. Neurosci. Res. 37:1994;777-787.
90. Lannfelt L., Folkesson R., Mohammed A.H., Winblad B., Hellgren D., Duff K., Hardy J. Alzheimer's Disease: molecular genetics and transgenic animal models. Behav. Brain Res. 57:1993;207-213.
91. Lee R.K.K., Wurtman R.J., Cox A.J., Nitch R.M. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc. Natl. Acad. Sci. 92:1995;8083-8087.
92. Malouf A.T. Effect of β-amyloid peptides on neurons in hippocampal slice cultures. Neurobiol. Aging. 13(5):1992;543-551.
93. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 228:1985;1115-1117.
94. Masliah E., Cole G., Shimohama S., Hansen L., DeTeresa R., Terry R.D., Saitoh T. Differential involvement of protein kinase C isozymes in Alzheimer's disease. J. Neurosci. 10(7):1990;2113-2124.
95. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 16(8):1996;5795-5811.
96. Masters C.L., Beyreuther K. Molecular neuropathology of Alzheimer's disease. Arzneim.-Forsch./Drug Res. 45(1):1995;410-412.
97. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82:1985;4245-4248.
98. McGeer P.L., McGeer E.G., Suzuki J., Dolman C.E., Nagai T. Aging Alzheimer's disease and the cholinergic system of the basal forebrain. Neurology. 34:1984;741-745.
99. Mehraein P., Rothemund E. Neuroanatomical correlates of the amnestic syndrome. Arch. Psychiatr. Nervenkrankh. 222(2-3):1976;153-176.
100. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301:1993;41-52.
101. Milner B. Disorders of learning and memory after temporal lobe lesions in man. Clin. Neurosurg. 19:1972;421-446.
102. Moran P.M., Higgins L.S., Cordell B., Moser P.C. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. Natl. Acad. Sci. 92:1995;5341-5345.
103. Moran M.A., Mufson E.J., Gomez-Ramos P. Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropath. 85(4):1993;362-369.
104. s in rat brain cortex. Neuroreport. 6(4):1995;633-636.
105. Mufson E.J., Conner J.M., Kordower J.H. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport. 6(7):1995;1063-1066.
106. Multhaup G. Identification and regulation of the high affinity biding site of the Alzheimer's disease amyloid precursor (APP) to glycosaminoglycans. Biochimie. 76:1994;304-311.
107. Multhaup G., Mechler H., Masters C.L. Characterization of the high affinity heparin biding site of the Alzheimer's disease βA4 amyloid precursor protein (APP) and its enhancement by zinc (II). J. Molec. Recog. 8(4):1995;247-257.
108. Muramoto O., Kuru Y., Sugishita M., Toyokura Y. Pure memory loss with hippo-campal lesions: a pneumoencephalographic study. Arch. Neurol. 36(1):1979;54-56.
109. Nabeshima T., Nitta A. Memory impairment and neuronal dysfunction induced by beta-amyloid protein in rats. Tohoku J. Exp. Med. 174(3):1994;241-249.
110. Nakamura T., Shoji M., Harigaya Y., Watanabe M., Hosoda K., Cheung T.T., Shaffer L.M., Golde T.E., Younkin L.H., Younkin S.G. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann. Neurol. 36(6):1994;903-911.
111. Nathan B.P., Chang K.-C., Bellosta S., Brisch E., Ge N., Mahley R.W., Pitas R.E. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270(34):1995;19791-19799.
112. Nitch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., Wurtman R.J. Evidence for a membrane defect in Alzheimer's disease brain. Proc. Natl. Acad. Sci. 89(5):1992;1671-1675.
113. Nitch R.M., Slack B.E., Farber S.A., Borghesani P.R., Schulz J.G., Kim C., Felder C.C., Growdon J.H., Wurtman R.J. Receptor coupled amyloid precursor processing. Ann. N.Y. Acad. Sci. 695:1993;122-127.
114. Nitch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 258:1992;304-307.
115. Nitch R.M., Slack B.E., Farber S.A., Schulz J.G., Deng M., Kim C., Borghesani P.R., Korver W., Wurtman R.J., Growdon J.H. Regulation of proteolytic processing of the amyloid β-protein precursor of Alzheimer's disease in transfected cell lines and in brain slices. J. Neural. Transm. 44(Suppl.):1994;21-27.
116. Nitch R.M., Wurtman R.J., Growdon J.H. Regulation of proteolytic processing of the amyloid β-protein precursor by first messengers. Arzneim.-Forsch./Drug Res. 45(1):1995;435-438.
117. Nixon R.A., Cataldo A.M., Paskevich P.A., Hamilton D.J., Wheelock T.R., Kanaley-Andrews L. The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis. Ann. N.Y. Acad. Sci. 674:1992;65-88.
118. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31(1):1992;103-111.
119. Norstedt C., Caporaso G.L., Thyberg J., Gandy S.E., Greengard P. Identification of the Alzheimer β/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. J. Biol. Chem. 268(1):1993;608-612.
120. Oltersdorf T., Fritz L.C., Schenk D.B., Lieberburg I., Johnson-Wood K.L., Beattie E.C., Ward P.J., Blacher R.W., Dovey H.F., Sinha S. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexic-II. Nature. 341:1989;144-147.
121. Palmert M.R., Podlisny M.B., Witker D.S., Oltersdorf T., Younkin L.H., Selkoe D.J., Younkin S.G. The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc. Natl. Acad. Sci. 86(16):1989;6338-6342.
122. Paylor R., Rudy J.W., Wehner J.M. Acute phorbol ester treatment improves spatial learning performance in rats. Behav. Brain Res. 45:1991;189-193.
123. Paylor R., Morrison S.K., Rudy J.W., Waltrip L.T., Wehner J.M. Brief exposure to an enriches environment improves performance on the Morris water maze task and increases hippocampal cytosolic protein kinase C activity in young rats. Behav. Brain Res. 52:1992;49-59.
124. Pearson R.C.A., Gatter K.C., Powell T.P.S. The cortical relationships of certain basal ganglia and the cholinergic basal forebrain. Brain Res. 261:1983;327-330.
125. Perry E.K., Tomlinson B.E., Blessed G., Bergman K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2:1978;1457-1459.
126. Pike C.J., Walencewicz-Wassermann A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of β-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64(1):1995;253-265.
127. Price J.L., Stern R. Individual cells in the nucleus basalis-diagonal band complex have restricted axonal projections to the cerebral cortex in the rat. Brain Res. 269:1983;352-356.
128. Reinikainen K.J., Reikkinen P.J., Halonen T., Laakso M. Decreased muscarinic receptor binding in cerebral cortex and hippocampus i Alzheimer's disease. Life Sciences. 41(4):1987;453-461.
129. M.R. Roberson, K. Kolasa, D.S. Parsons, L.E. Harrell, Cholinergic denervation and hippocampal sympathetic ingrowth differentially alter hippocampal muscarinic receptors over time, 1996 (submitted).
130. N.K. Robakis, b-amyloid and amyloid precursor protein, in: R.D. Terry, R. Katzman and K.L. Bick (Eds.), Alzheimer's Disease, Raven Press, New York, 1994, pp. 317-325.
131. Roch J.-M., Masliah E., Roch-Leveq A.-C., Sundsmo M.P., Otero D.A., Veinbergs I., Saitoh T. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid β/A4 protein precursor. Proc. Natl. Acad. Sci. 91:1994;7450-7454.
132. Samuel W., Masliah E., Hill L.R., Butters N., Terry R. Hippocampal connectivity and Alzheimer's dementia: effects of synapse loss and tangle frequency in a two-component model. Neurology. 44:1994;2081-2088.
133. Samuel W., Terry R.D., DeTeresa R., Butters N., Masliah E. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer's dementia. Arch. Neurol. 51(8):1994;772-778.
134. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D., Strittmatter W.J. Apolipoprotein E associates with β-amyloid peptide of Alzheimer's disease to form novel monofibrils. J. Clin. Invest. 94:1994;860-869.
135. Schubert D., LaCorbiere M., Saitoh T., Cole G. Characterization of an amyloid beta precursor protein that binds heparin and contains tyrosine sulfate. Proc. Natl. Acad. Sci. 86(6):1989;2066-2069.
136. Schwab M.E., Otten U., Agid Y., Thoenen H. Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra. Brain Res. 168:1979;473-483.
137. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15(9):1995;6213-6221.
138. Seiler M., Schwab M.E. Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res. 300:1984;33-39.
139. Shimohama S., Fujimoto S., Tresser N., Richey P., Perry G., Whitehouse P.J., Homma Y., Takenawa T., Taniguchi T., Suenaga T., Kimura J. Aberrant phosphoinositide metabolism in Alzheimer's disease. Ann. N.Y. Acad. Sci. 695:1993;46-49.
140. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.-D., McKay D.M., Tintner R., Frangione B., Younkin S.G. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science. 258:1992;126-129.
141. Sisodia S.S. β-amyloid precursor proten cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA. 89:1992;6075-6079.
142. Sisodia S.S. Secretion of the β-amyloid precursor protein. Ann. N.Y. Acad. Sci. 695:1993;53-57.
143. Sisodia S.S., Koo E.H., Beyreuther K., Unterbeck A., Price D.L. Evidence that β-amyloid protein in Alzheimer's disease is not derived by normal processing. Science. 248:1990;492-495.
144. Sisodia S.S., Price D.L. Role of the β-amyloid protein in Alzheimer's disease. FASEB J. 9:1995;366-370.
145. Slack B.E., Nitch R.M., Livneh E., Kunz G.M., Eldar H., Wurtman R.J. Regulation of amyloid precursor protein release by protein kinase C in swiss 3T3 fibroblasts. Ann. N.Y. Acad. Sci. 695:1993;128-131.
146. Small D.H., Moir R.D., Fuller S.J., Michaelson S., Bush A.I., Li Q.-X., Milward E., Hilbich C., Weidemann A., Beyreuther K., Masters C.L. A protease associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer's disease. Biochemistry. 30:1991;10795-10799.
147. Small D.H., Nurcombe V., Moir R., Michaelson S., Monard D., Beyreuther K., Masters C.L. Association and release of the amyloid protein precursor of Alzheimer's disease from chick brain extracellular matrix. J. Neurosci. 12(11):1992;4143-4150.
148. Squire L.R., Zola-Morgan S. The medial temporal lobe memory system. Science. 253:1991;1380-1386.
149. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Proc. Natl. Acad. Sci. 92:1995;4725-4727.
150. Suhara T., Inoue O., Kobayashi K., Suzuki K., Tateno Y. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci. Lett. 149:1993;225-228.
151. Suzuki T., Nairn A.C., Gandy S.E., Greengard P. Phosphorylation of Alzheimer amyloid precursor protein by protein kinase C. Neuroscience. 48(4):1992;755-761.
152. Svensson A.-L., Alafuzoff I., Nordberg A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 596:1992;142-148.
153. Tagawa K., Maruyama K., Ishiura S. Amyloid βA4 precursor protein (APP) processing in lysosomes. Ann. N.Y. Acad. Sci. 674:1992;129-137.
154. Tagawa K., Kunishita T., Maruyama K., Yoshikawa K., Kominami E., Tsuchiya T., Suzuki K., Tabira T., Sugita H., Ishiura S. Alzheimer's disease amyloid beta-clipping enzyme (APP secretase): identification, purification, and characterization of the enzyme. Biochem. Biophys. Res. Commun. 177(1):1991;377-387.
155. Takadera T., Sakura N., Mohri T., Hashimoto T. Toxic effect of β-amyloid peptide (β 22-35) on the hippocampal neuron and its prevention. Neurosci. Lett. 161(1):1993;41-44.
156. Tanaka S., Nakamura S., Ueda K., Kameyama M., Shiojiri S., Takahashi Y., Kitaguchi N., Ito H. Three types of amyloid precursor protein mRNA in human brain: their differential expression in Alzheimer's disease. Biochem. Biophys. Res. Commun. 157(2):1988;472-479.
157. Tanzi R.E., Gusells J.F., Watkins P.C., Brush G.A.P., St. George-Hyslop P., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., Neve R.L. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 235:1987;880-884.
158. P. Taylor, J.H. Brown, Acetylcholine, in: G.J. Siegel, B.W. Agranoff, R.W. Albers, P.B. Molinoff (Eds.), Basic Neurochemistry, Raven Press, New York, 1994, pp. 231-260.
159. R.D. Terry, E. Masliah, L.A. Hansen, Structural basis of the cognitive alterations in Alzheimer disease, in: R.D. Terry, R. Katzman, K.L. Bick (Eds.), Alzheimer Disease, Raven Press, New York, 1994, pp. 179-196.
160. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss in the major correlate of cognitive impairment. Ann. Neurol. 30:1991;572-580.
161. Ueda K., Fukui Y., Kageyama H. Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein. Brain Res. 639(2):1994;240-244.
162. van Gool W.A., Kuiper M.A., Walstra G.J., Wolters E.C., Bolhuis P.A. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 37(2):1995;277-279.
163. Van Nostrand W.E., Schmaier A.H., Wagner S.L. Potential role of protease nexin-2/amyloid β-protein precursor as a cerebral anticoagulant. Ann. N.Y. Acad. Sci. 674:1992;243-252.
164. Van Nostrand W.E., Wagner S.L., Shankle W.R., Farrow J.S., Dick M., Rozemuller J.M., Kuiper M.A., Wolters E.C., Zimmerman J., Cotman C.W., Cunningham D.D. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl. Acad. Sci. USA. 89:1992;2551-2555.
165. B.H. Wainer, T.L. Steininger, J.D. Roback, M.A. Burke-Watson, E.J. Mufson, J. Kordower, Ascending cholinergic pathways: functional organization and implications for disease models, in: A.C. Cuello (Ed.), Cholinergic Function and Dysfunction: Progress in Brain Research, vol. 98, Elsevier Science, Amsterdam, 1993, pp. 9-30.
166. 5) of muscarinic receptors. J. Neurochem. 62(4):1994;1345-1351.
167. Wallace W.C., Lieberburg I., Schenk D., Vigo-Pelfrey C., Davis K.L., Haroutunian V. Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J. Neurosci. 15(7):1995;4896-4905.
168. Wallace W.C., Bragin V., Robakis N.K., Sambamurti K., VanderPutten D., Merril C.R., Davis K.L., Santicci A.C., Haroutunian V. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Mol. Brain Res. 10:1991;173-178.
169. Wallace W., Ahlers S.T., Gotlib J., Bragin V., Sugar J., Gluck R., Shea P.A., Davis K.L., Haroutunian V. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc. Natl. Acad. Sci. 90:1993;8712-8716.
170. Wan R.Q., Pang K., Olton D.S. Hippocampal and amygdaloid involvement in non-spatial and spatial working memory in rats: effects of delay and interference. Behav. Neurosci. 108(5):1994;866-882.
171. Weidemann A., Konig G., Bunke D., Fisher P., Salbaum J.M., Masters C.L., Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 57:1989;115-126.
172. C.E. Wells, Organic syndromes: dementia, in: H.I. Kaplan, B.J. Sadock (Eds.), Comprehensive Textbook of Psychiatry, 4th ed., Williams & Wilkins, Baltimore, 1985, p. 851.
173. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10(2):1981;115-126.
174. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
175. Whitson J.S., Selkoe D.J., Cotman C.W. Amyloid β protein enhances the survival of hippocampal neurons in vitro. Science. 243:1989;1488-1490.
176. Wible C.G., Shiber J.R., Olton D.S. Hippocampus, fimbria-fornix, amygdala, and memory: object discrimination in rats. Behav. Neurosci. 106(5):1992;751-761.
177. Williams L.R., Varon S., Peterson G.M., Wictorin C., Fischer W., Bjorkland A., Gage F.H. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc. Natl. Acad. Sci. USA. 83:1986;9231-9235.
178. Wisniewski H.M., Wegiel J., Kotula L. Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Neuropath. App. Neurobiol. 22:1996;3-11.
179. Wolf B.A., Wertkin A.M., Jolly Y.C., Yasuda R.P., Wolfe B.B., Konrad R.J., Manning D., Ravi S., Williamson J.R., Lee V.M. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid β-protein production in human neuronal NT2N cells. J. Biol. Chem. 270(9):1995;4916-4922.
180. Xu H., Greengard P., Gandy S. Regulated formation of Golgi secretory vesicles containing Alzheimer β-amyloid precursor protein. J. Biol. Chem. 270(40):1995;23243-23245.
181. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245:1989;417-420.
182. Younkin S.G., Goodridge B., Katz J., Lockett G., Nafziger D., Usiak M.F., Younkin L.H. Molecular forms of acetylcholinesterases in Alzheimer's disease. Fed. Proc. 45(13):1986;2982-2988.
183. Zola-Morgan S., Squire L.R., Amaral D.G., Suzuki W. Lesions of perirhinal and parahippocampal cortex that spare the amygdala and hippocampal formation produce severe memory impairment. J. Neurosci. 9(12):1989;4355-4370.
184. Zola-Morgan S., Squire L.R., Ramus S.J. Severity of memory impairment in monkeys as a function of locus and extent of damage within the medial temporal lobe memory system. Hippocampus. 4(4):1994;483-495.